natgillin/translations-raw huggingface dataset:
For the full list of side effects and restrictions with Cablivi, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Cablivi glejte navodilo za uporabo.
Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. 
Učinkovina zdravila Cablivi, kaplacizumab, je nanotelo (majhno protitelo), ki je zasnovano za pritrditev na von Willebrandov faktor tako, da zavira njegovo delovanje na krvne ploščice.
Cablivi is started with a dose of 10 mg given by injection into a vein before plasma exchange. 
Zdravljenje z zdravilom Cablivi se začne z odmerkom 10 mg in se daje z injiciranjem v veno pred izmenjavo plazme.
During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot). 
Med epizodo pridobljene trombotične trombocitopenične purpure v majhnih krvnih žilah nastajajo strdki in bolnik ima nizko število krvnih ploščic (sestavine krvi, ki sodelujejo pri strjevanju krvi).
Cablivi is a medicine used for treating adults who have an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a blood clotting disorder. 
Zdravilo Cablivi se uporablja za zdravljenje odraslih, ki imajo epizode pridobljene trombotične trombocitopenične purpure, motnje strjevanja krvi.
The study found that platelet count was likely to return to the normal range more quickly in patients treated with Cablivi compared with those receiving placebo. 
V študiji so ugotovili, da je bilo verjetneje, da se število krvnih ploščic na normalno raven vrne hitreje pri bolnikih, zdravljenih z zdravilom Cablivi, kot pri bolnikih, zdravljenih s placebom.
How is Cablivi used? 
Kako se zdravilo Cablivi uporablja?
How does Cablivi work? 
Kako zdravilo Cablivi deluje?
Cablivi can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Cablivi je le na recept.
von Willebrand factor acts on platelets to cause them to stick together and form blood clots. 
Ta deluje na krvne ploščice in povzroči, da se zlepijo in tvorijo krvne strdke.
Cablivi contains the active substance caplacizumab. 
Zdravilo Cablivi vsebuje učinkovino kaplacizumab.
Then continue your treatment as before. 
Potem zdravljenje nadaljujte kot prej.
Date of first authorisation: 22 November 2018 
Datum prve odobritve: 22. november 2018
This will help by: 
To lahko pomaga, ker:
Blood tests may also show: 
Preiskave krvi lahko pokažejo tudi:
3; these characteristics were similar between treatment groups. 
3; te značilnosti so bile med terapevtskima skupinama podobne.
Do not give this medicine to anybody aged less than 18 years. 
Tega zdravila ne smete dati nikomur, ki je mlajši od 18 let.
Talk to your doctor about what you can do to avoid infecting other people. 
Z zdravnikom se posvetujte, kaj lahko storite, da ne boste okužili drugih oseb.
The recommended dose is 1 tablet once a day. 
Priporočeni odmerek zdravila je 1 tableta enkrat na dan.
On study but missing data in window 
V študiji, toda z manjkajočimi podatki v oknu
The patient should not take 2 doses at one time. 
Bolnik ne sme vzeti 2 odmerkov naenkrat.
Treatment results are shown in Table 5. 
Rezultati zdravljenja so prikazani v preglednici 5.
No Virologic Data Within the Time Window 
Brez viroloških podatkov znotraj časovnega okna
Your doctor may need to do additional tests to check your bones. 
Zdravnik vam bo morda moral opraviti dodatne preiskave za kontrolo kosti.
Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. 
Imunski sistem se vam lahko okrepi in se začne boriti proti okužbam, ki so bile že dolgo skrite v telesu.
• This medicine can be taken with food or between meals. 
• To zdravilo lahko vzamete hkrati s hrano ali med enim in drugim obrokom.
A similar effect was not seen in rats even at very high systemic exposure. 
Pri podganah podobnega učinka niso opazili niti pri zelo veliki sistemski izpostavljenosti.
It belongs to a group of medicines called ‘antiretroviral medicines'. 
Spada v skupino zdravil, imenovanih "protiretrovirusna zdravila".
mannitol, lactitol or maltitol), if taken regularly 
manitol, laktitol ali maltitol), če jih jemljete redno.
These tumours are unlikely to be of relevance to humans. 
Ni verjetno, da so ti tumorji pomembni za človeka.
Physicians are encouraged to register patients in this registry. 
Zdravnike prosimo, naj takšne bolnice zabeležijo v ta register.
Passing HIV to others 
Prenašanje virusa HIV na druge osebe
This should be considered when assessing a patient's ability to drive or operate machinery. 
To je treba upoštevati pri ocenjevanju bolnikove sposobnosti za vožnjo in upravljanje strojev.
There may be more than one in the bottle. 
V plastenki je lahko več kot eno sušilo.
Do not stop taking this medicine without first talking to your doctor. 
Ne prenehajte jemati tega zdravila, ne da bi se prej posvetovali z zdravnikom.
Discontinued study for Other Reasons 
Prenehanje sodelovanja v študiji zaradi drugih razlogov
If you take certain medicines your doctor may need to change the amount of doravirine you take. 
Če jemljete določena druga zdravila, vam bo zdravnik morda moral spremeniti količino doravirina, ki jo jemljete.
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. 
Obvestite zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Biliary excretion of unchanged medicinal product may contribute to the elimination of doravirine, but this elimination route is not expected to be significant. 
Biliarno izločanje nespremenjenega zdravila lahko pripomore k izločanju doravirina, vendar ni pričakovati, da bi bila to pomembna pot za odstranjevanje.
ISG-DSG, Difference (95 % CI)* 
ISG-DSG, razlika (95 % IZ)*
• increasing the number of white blood cells called ‘CD4 
• poveča število belih krvnih celic, imenovanih "celice CD4
Cross-resistance has been observed among NRTIs. 
Med NRTI je bila opažena navzkrižna odpornost.
• Do not use this medicine after the expiry date which is stated on the bottle after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki poleg oznake EXP.
• feeling of incomplete defecation 
• občutek nepopolnega iztrebljanja
Delstrigo may have a minor influence on the ability to drive and use machines. 
Zdravilo Delstrigo lahko ima manjši vpliv na sposobnost za vožnjo in upravljanje strojev.
The most frequently reported adverse reactions considered possibly or probably related to doravirine were nausea (4 %) and headache (3 %). 
Najpogosteje poročana neželena učinka, ki veljata za morda ali verjetno povezana z doravirinom, sta bila navzea (4 %) in glavobol (3 %).
Investigations Common alanine aminotransferase increased 
Preiskave Pogosti zvišanje alanin-aminotransferaze
NNRTI substitutions and use of doravirine 
Z NNRTI povezane substitucije in uporaba doravirina
These medicinal products include, but are not limited to the following: 
Med takšna spadajo naslednja zdravila (toda ne samo ta):
Co-administration should be avoided. 
Sočasni uporabi se je treba izogniti.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, talk to your doctor about the risks and benefits of taking Delstrigo. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se z zdravnikom posvetujte o tveganjih in koristih jemanja zdravila Delstrigo.
GM: Geometric mean, %CV: Geometric coefficient of variation 
GS: geometrična sredina, % KV: geometrični koeficient variacije
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), or very rare (< 1/10,000). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) ali zelo redki (< 1/10.000).
• Do not take two doses of Delstrigo at the same time to make up for a missed dose. 
• Ne vzemite dveh odmerkov zdravila Delstrigo hkrati, da bi nadomestili izpuščeni odmerek.
Antiviral activity in cell culture 
Protivirusna aktivnost v celični kulturi
HIV is spread by contact with blood or through sexual contact with a person with HIV. 
Virus HIV se širi s stikom z okuženo krvjo ali s spolnimi stiki z okuženo osebo.
If you stop taking Delstrigo, your doctor will need to check your health often and do blood tests regularly for several months to check your HIV infection. 
Če nehate jemati zdravilo Delstrigo, bo moral zdravnik pogosto preverjati vaše zdravstveno stanje in še več mesecev redno izvajati preiskave krvi za spremljanje okužbe s HIV.
Following oral administration, lamivudine is rapidly absorbed and extensively distributed. 
Po peroralni uporabi se lamivudin hitro absorbira in obsežno porazdeli.
The clinical relevance of a 5-10 fold change reduction in susceptibility is unknown. 
Klinični pomen od 5- do 10-kratnega zmanjšanja občutljivosti ni znan.
Table 3: Resistance development up to week 96 in protocol defined virologic failure population + early discontinuation population 
Preglednica 3: Razvoj odpornosti do 96. tedna v populaciji z virološkim neuspehom, opredeljenim po protokolu in v populaciji z zgodnjim prenehanjem
The doravirine-based regimens demonstrated consistent efficacy across demographic and baseline prognostic factors. 
Shemi zdravljenja na osnovi doravirina sta bili dosledno učinkoviti po vseh demografskih in izhodiščnih prognostičnih dejavnikih.
There is insufficient information on the effects of tenofovir in newborns/infants. 
O učinkih tenofovirja pri novorojenčkih/dojenčkih ni dovolj informacij.
Although the effect of supplementation with calcium and Vitamin D was not studied, such supplementation may be beneficial in all patients. 
Učinek dodajanja kalcija in vitamina D sicer ni raziskan, toda njuno dodajanje lahko koristi vsem bolnikom.
• abnormal dreams, difficulty in sleeping (insomnia) 
• nenormalne sanje, težave s spanjem (nespečnost)
These differences in pharmacokinetics are not clinically relevant. 
Te razlike v farmakokinetiki niso klinično pomembne.
Parameter GM ( %CV) 
Parameter GS (% KV)
Table 1: Interactions between the individual components of Delstrigo and other medicinal products 
Preglednica 1: Medsebojna delovanja posameznih sestavin zdravila Delstrigo in drugih zdravil
Doravirine has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. 
Doravirina niso ocenili pri bolnikih s predhodnim virološkim neuspehom katerega koli drugega protiretrovirusnega zdravljenja.
Delstrigo Once Daily ISG 
Zdravilo Delstrigo enkrat na dan ISG
• Periodic Safety Update Reports (PSURs) 
• Redno posodobljena poročila o varnosti zdravila (PSUR)
The marketing authorization holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Other reasons include: lost to follow-up, non-compliance with study drug, physician decision, protocol deviation, withdrawal by subject. 
Drugi razlogi vključujejo: izgubljeni tekom spremljanja, nesodelovanje (nekomplianca) pri uporabi raziskovanega zdravila, zdravnikova odločitev, kršitev protokola, umik s strani preiskovanca.
*The 95 % CI for the treatment difference was calculated using stratum-adjusted Mantel-Haenszel method. 
*95-odstotni interval zaupanja za razliko med zdravljenji je izračunan po Mantel-Haenszelovi metodi s prilagoditvijo za stratume.
Some patients required hospitalisation and renal replacement therapy. 
Nekateri bolniki so potrebovali sprejem v bolnišnico in nadomestno zdravljenje ledvic.
Blood tests may also show: • increased levels in liver enzymes (ALT) 
Preiskave krvi lahko pokažejo tudi: • zvišanje jetrnih encimov (ALT)
*For Week 96, certain subjects with missing HIV-1 RNA were excluded from the analysis. 
*Pri analizi za 96. teden so bili določeni preiskovanci z manjkajočim HIV-1 RNA izkjučeni iz analize.
Women with HIV should not breastfeed because HIV can be passed on to babies through breast milk. 
Ženske, okužene z virusom HIV, ne smejo dojiti, ker lahko virus z mlekom prenesejo na otroka.
Lamivudine has been identified in breast-fed newborns/infants of treated women. 
Lamivudin so zaznali pri dojenih novorojenčkih/dojenčkih zdravljenih žensk.
Tell your doctor right away if you start having any new symptoms after starting your HIV medicine. 
Zdravnika morate takoj obvestiti, če se vam po začetku jemanja zdravila proti virusu HIV pojavijo kakšni novi simptomi.
• Swallow the tablet whole (do not crush or chew). 
• Tableto zaužijte celo (ne smete je drobiti ali žvečiti).
 = increase, ↓ = decrease, ↔ = no change CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily *AUC0- for single dose, AUC0-24 for once daily. 
 = povečanje, ↓ = zmanjšanje, ↔ = brez spremembe IZ = interval zaupanja, 1x/dan = enkrat na dan, 2x/dan = dvakrat na dan *AUC0- za enkratni odmerek, AUC0-24 za uporabo enkrat na dan
This can happen when you start taking any HIV medicine, including Delstrigo. 
Ta se lahko pojavi, ko začnete jemati katero koli zdravilo proti virusu HIV, tudi zdravilo Delstrigo.
If you accidentally take more, contact your doctor. 
Če pomotoma vzamete več zdravila, se posvetujte z zdravnikom.
A panel of 96 diverse clinical isolates containing NNRTI-associated mutations was evaluated for susceptibility to doravirine in the presence of 10 % foetal bovine serum. 
Skupino 96 različnih kliničnih izolatov, ki so imeli z NNRTI povezane mutacije, so ovrednotili glede občutljivosti na doravirin v prisotnosti 10 % fetalnega govejega seruma.
In humans, the only known metabolite is the trans-sulphoxide metabolite (approximately 5 % of an oral dose after 12 hours). 
Pri človeku je edini znani presnovek transsulfoksidni presnovek (približno 5 % peroralnega odmerka po 12 urah).
You should not take Delstrigo if your doctor has told you that the virus causing your infection is resistant to any of the medicines in Delstrigo. 
Zdravila Delstrigo ne smete jemati, če vam je zdravnik povedal, da je virus, ki povzroča okužbo pri vas, odporen proti kateri koli učinkovini v zdravilu Delstrigo.
ombitasvir/paritaprevir/ ritonavir and dasabuvir +/ritonavir 
ombitasvir/paritaprevir/ ritonavir in dasabuvir +/ritonavir
Successful genotype, n Genotypic resistance to DOR or control (DRV or EFV) 2 (DOR) 
Genotipska odpornost proti DOR ali kontrola (DRV ali EFV) 2 (DOR)
In vitro studies have determined that neither tenofovir disoproxil nor tenofovir are substrates for the CYP450 enzymes. 
Študije in vitro so pokazale, da niti dizoproksiltenofovirat niti tenofovir nista substrata encimov CYP450.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolniki z redkimi prirojenimi motnjami, kot so intoleranca za galaktozo, popolno pomanjkanje laktaze ali malabsorpcija glukoze-galaktoze, ne smejo jemati tega zdravila.
Very rare peripheral neuropathy (or paraesthesia)* 
Zelo redki periferna nevropatija (ali parestezije)*
You can still pass on HIV when taking Delstrigo, although effective therapy lowers the risk. 
Tudi med jemanjem zdravila Delstrigo lahko še vedno prenašate virus HIV, čeprav učinkovito zdravljenje zmanjša to tveganje.
EU/1/18/1333/001 EU/1/18/1333/002 90 (3 x 30) tablets 
EU/1/18/1333/001 EU/1/18/1333/002 90 (3 x 30) tablet
Worsening of hepatitis B infection 
Poslabšanje okužbe z virusom hepatitisa B
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition. 
Ne ocenjujejo ga kot vzročno povezanega z dizoproksiltenofoviratom v odsotnosti te motnje.
Information regarding potential medicinal product interactions with other antiretroviral medicines is not provided. 
Tukaj niso navedene informacije o možnih medsebojnih delovanjih zdravila z drugimi protiretrovirusnimi zdravili.
New onset or worsening renal impairment 
Novonastala okvara ledvic ali poslabšanje okvare ledvic
This is because other medicines may affect how Delstrigo works, and Delstrigo might affect the way some other medicines work. 
Druga zdravila namreč lahko vplivajo na delovanje zdravila Delstrigo pa tudi zdravilo Delstrigo lahko vpliva na delovanje nekaterih drugih zdravil.
Week 24 N=223 
24. teden N = 223
Excretion of unchanged medicinal product via urinary excretion is minor. 
Izločanje nespremenjenega zdravila z urinom je majhno.
Includes subjects who discontinued because of adverse event (AE) or death if this resulted in no virologic data on treatment during the specified window. 
Vključuje preiskovance, ki so prenehali sodelovati zaradi neželenega učinka (NU) ali smrti, če je to povzročilo, da niso imeli viroloških podatkov med zdravljenjem v opredeljenem oknu.
No human data on the effect of Delstrigo on fertility are available. 
Podatkov o vplivu zdravila Delstrigo na plodnost pri človeku ni.
• muscle weakness, weakening of the bones (with bone pain and sometimes resulting in fractures) 
• oslabelost mišic, oslabitev kosti (z bolečinami v kosteh in včasih z zlomi)
The pharmacokinetics of lamivudine and tenofovir have not been studied in subjects older than 65 years. 
Farmakokinetike lamivudina in tenofovirja niso raziskali pri osebah, starejših od 65 let.
Table 5: Efficacy response (Snapshot approach) in the DRIVE-SHIFT study 
Preglednica 5: Odziv učinkovitosti (metoda "Snapshot") v študiji DRIVE-SHIFT
Week 48 and 96 outcomes for DRIVE-FORWARD and DRIVE-AHEAD are provided in Table 4. 
Izidi v preskušanjih DRIVE-FORWARD in DRIVE-AHEAD 48. in 96. teden so prikazani v preglednici 4.
The use of Delstrigo in people aged less than 18 years has not yet been studied. 
Uporaba zdravila Delstrigo pri osebah, mlajših od 18 let, še ni raziskana.
Discontinued study due to AE or Death 
Prenehanje sodelovanja v študiji zaradi NU ali smrti
Tenofovir is excreted in human milk. 
Tenofovir se izloča v materino mleko.
HIV is the virus that causes AIDS (‘acquired immune deficiency syndrome'). 
Virus HIV lahko povzroči aids (sindrom pridobljene imunske pomanjkljivosti).
• increased levels in liver enzymes (AST) 
• zvišanje jetrnih encimov (AST)
There are no data available on the safety of lamivudine when administered to babies less than three months old. 
Podatkov o varnosti lamivudina, uporabljenega pri dojenčkih, mlajših od treh mesecev, ni.
Delstrigo is used to treat HIV infection in people 18 years of age and older. 
Zdravilo Delstrigo se uporablja za zdravljenje okužbe s HIV pri osebah, starih 18 let ali več.
Keep desiccant inside the bottle and do not throw away until you have finished taking all of the medicine. 
Sušilo naj ostane v plastenki in se ga ne sme zavreči, dokler ne porabite vsega zdravila.
Lamivudine Lamivudine does not inhibit or induce CYP enzymes. 
Lamivudin Lamivudin ne zavira in ne inducira encimov CYP.
The effects of tenofovir disoproxil associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. 
Učinki sprememb MKG in biokemičnih označevalcev, povezanih z dizoproksiltenofoviratom, na dolgoročno zdravje kosti in tveganje za prihodnje zlome niso znani.
Delstrigo contains lactose monohydrate. 
Zdravilo Delstrigo vsebuje laktozo monohidrat.
Discuss your hepatitis B therapy with your doctor. 
O zdravljenju hepatitisa B se posvetujte z zdravnikom.
NRTI backbone M184I/V only K65R only K65R + M184I/V 
NRTI osnova samo M184I/V samo K65R K65R + M184I/V
Rare dyspnoea, tonsillar hypertrophy 
Redki dispneja, hipertrofija tonzil
Doravirine at a dose of 100 mg once daily is not likely to have a clinically relevant effect on the plasma concentrations of medicinal products that are dependent on transport proteins for absorption and/or elimination or that are metabolised by CYP enzymes. 
Ni verjetno, da bi doravirin v odmerku 100 mg enkrat na dan klinično pomembno vplival na plazemsko koncentracijo zdravil, ki so za absorpcijo in/ali odstranjevanje odvisna od transportnih beljakovin oziroma se presnavljajo z encimi CYP.
The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ class and frequency. 
Neželeni učinki, domnevno (vsaj morda) povezani z zdravljenjem, so navedeni spodaj po organskih sistemih in pogostnosti.
The EC50 values for tenofovir were in the range of 0.04-8.5 microM. 
Vrednosti EC50 tenofovirja so bile v razponu od 0,04 do 8,5 mikroM.
The highest frequency category reported in the 3TC or TDF Summary of Product Characteristics is used. 
Uporabljena je najvišja kategorija pogostnosti, navedena v povzetku glavnih značilnosti zdravila za 3TC ali TDF.
No dose adjustment is required. 
Odmerka ni treba prilagoditi.
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, 
• zdravila (običajno tekočine), ki vsebujejo sorbitol ali druge sladkorne alkohole (kot so ksilitol,
The muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells. 
Bolečine v mišicah, šibkost mišic in znižanje kalija ali fosfata v krvi se lahko pojavijo zaradi okvare celic ledvičnih tubulov.
If bone abnormalities are suspected, then appropriate consultation should be obtained. 
V primeru suma na kostne nepravilnosti je potrebno ustrezno posvetovanje.
During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment. 
Med uvodno fazo kombiniranega protiretrovirusnega zdravljenja se lahko pri bolnikih, katerih imunski sistem se odzove, razvije vnetni odziv na indolentne ali rezidualne oportunistične okužbe (kot so npr. okužba z Mycobacterium avium, z virusom citomegalije, pljučnica zaradi Pneumocystis jirovecii [PCP] ali tuberkuloza), zaradi katerih so lahko potrebne dodatne preiskave in zdravljenje.
A large amount of data on pregnant women (more than 3,000 outcomes from first trimester) taking the individual active component lamivudine in combination with other antiretrovirals indicates no malformative toxicity. 
Obsežni podatki pri nosečnicah (več kot 3.000 izidov od prvega trimesečja), ki so jemale samostojno učinkovino lamivudin v kombinaciji z drugimi protiretrovirusnimi zdravili, ne kažejo malformacijskih toksičnih učinkov.
While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission of HIV-1, a residual risk cannot be excluded. 
Dokazano je sicer, da učinkovita supresija virusov s protiretrovirusnim zdravljenjem bistveno zmanjša tveganje za spolni prenos HIV-1, vendar določenega preostalega tveganja ni mogoče izključiti.
In a population pharmacokinetic analysis, which included subjects with CrCl between 17 and 317 mL/min, renal function did not have a clinically relevant effect on doravirine pharmacokinetics. 
V populacijski farmakokinetični analizi, ki je vključevala preiskovance z očistkom kreatinina med 17 in 317 ml/min, delovanje ledvic ni klinično pomembno vplivalo na farmakokinetiko doravirina.
EC50 values were in the range of 0.003 to 15 microM (1 microM = 0.23 micrograms per mL). 
Vrednosti EC50 so bile v razponu od 0,003 do 15 mikroM (1 mikroM = 0,23 mikrograma na ml).